16 September 2026 – Two Australian organisations dedicated to seeking better outcomes for people with cancer — GenesisCare and Omico — are teaming up to bring precision oncology to more patients facing incurable, advanced or poor prognosis cancers.

The new collaboration between not-for-profit Omico and GenesisCare’s cancer care network of 50 locations focuses on Omico’s Cancer Screening Program (CaSP), which provides eligible patients with comprehensive genomic profiling (CGP) and matching to biomarker-led treatments and trials at no cost. The partnership aims to support routine access to CaSP for eligible GenesisCare patients and increased coordination around clinical trial opportunities. For some patients, this can uncover treatment options that may not otherwise have been identified, with the potential to extend lives.

GenesisCare Medical Oncologist Tony Michele said: “GenesisCare is pleased to work with Omico more closely, as we prepare to extend the promise of genomic profiling to more patients facing challenging cancers. We want to increase access to genomic profiling and biomarker-matched clinical trials, while accelerating our knowledge of genomic cancer medicine for the benefit of future patients. We hope that, over time, this approach will become routinely available for all patients who can benefit, delivering better outcomes and less side effects for patients.”

Omico Chief Executive Officer Ian Black said: “Partnerships across the health system are essential to improving outcomes for people with cancer. By working together, Omico and GenesisCare can combine our complementary expertise, networks and capabilities to reach more people and contribute to a stronger, more connected approach to precision oncology in Australia.”

The collaboration will include a coordinated approach to identify and refer eligible patients at GenesisCare sites to CaSP. Following referral from their GenesisCare oncologist, patients who opt-in to CaSP can access CGP and will receive recommendations for potential biomarker-led treatment and clinical trial opportunities. Their participation also contributes to Omico’s observational cohort study, Research Registry and Biobank, building valuable resources to support future cancer research and advances in care.

-Ends-

 

About GenesisCare Australia: GenesisCare is a proudly Australian-run cancer care provider, specialising in radiation therapy with a growing footprint in medical oncology, theranostics and personalised medicine. Our relentless pursuit for better care is reflected in our modern treatment techniques, technology and contemporary service experience. Our dedicated doctors and research team partner globally to be first movers in bringing clinical innovations to patients close to home. Around 35,000 people a year entrust us with their care across more than 50 locations nationally. For more information, visit www.genesiscare.com.

About Omico: Omico is an independent, national, not-for-profit organisation changing the way we fight cancer. We provide Australians with equitable access to precision oncology while accelerating its adoption across research and care. By translating the latest scientific advances into clinical care, research and real-world evidence, we generate evidence needed to inform health policy and system reform. We unite Australia’s leading cancer institutes, researchers, clinicians, industry partners, advocacy groups and government to advance precision oncology through molecular profiling, biomarker-led clinical trials, personalised cancer risk management and real-world evidence, helping improve outcomes for Australians with cancer.